Literature DB >> 28181348

Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Michael R Harowicz1, Ashirbani Saha1, Lars J Grimm1, P Kelly Marcom2, Jeffrey R Marks3, E Shelley Hwang4, Maciej A Mazurowski1,5,6.   

Abstract

PURPOSE: To assess the ability of algorithmically assessed magnetic resonance imaging (MRI) features to predict the likelihood of upstaging to invasive cancer in newly diagnosed ductal carcinoma in situ (DCIS).
MATERIALS AND METHODS: We identified 131 patients at our institution from 2000-2014 with a core needle biopsy-confirmed diagnosis of pure DCIS, a 1.5 or 3T preoperative bilateral breast MRI with nonfat-saturated T1 -weighted MRI sequences, no preoperative therapy before breast MRI, and no prior history of breast cancer. A fellowship-trained radiologist identified the lesion on each breast MRI using a bounding box. Twenty-nine imaging features were then computed automatically using computer algorithms based on the radiologist's annotation.
RESULTS: The rate of upstaging of DCIS to invasive cancer in our study was 26.7% (35/131). Out of all imaging variables tested, the information measure of correlation 1, which quantifies spatial dependency in neighboring voxels of the tumor, showed the highest predictive value of upstaging with an area under the curve (AUC) = 0.719 (95% confidence interval [CI]: 0.609-0.829). This feature was statistically significant after adjusting for tumor size (P < 0.001).
CONCLUSION: Automatically assessed MRI features may have a role in triaging which patients with a preoperative diagnosis of DCIS are at highest risk for occult invasive disease. LEVEL OF EVIDENCE: 4 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2017;46:1332-1340.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  MRI; breast cancer; ductal carcinoma in situ; invasive carcinoma; upstaging

Mesh:

Year:  2017        PMID: 28181348      PMCID: PMC5910028          DOI: 10.1002/jmri.25655

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  36 in total

1.  Detection of invasive components in cases of breast ductal carcinoma in situ on biopsy by using apparent diffusion coefficient MR parameters.

Authors:  Naoko Mori; Hideki Ota; Shunji Mugikura; Chiaki Takasawa; Junya Tominaga; Takanori Ishida; Mika Watanabe; Kei Takase; Shoki Takahashi
Journal:  Eur Radiol       Date:  2013-06-04       Impact factor: 5.315

2.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

3.  Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.

Authors:  Mirjan Nadrljanski; Ružica Maksimović; Vesna Plešinac-Karapandžić; Marina Nikitović; Biljana Marković-Vasiljković; Zorica Milošević
Journal:  Eur J Radiol       Date:  2014-05-16       Impact factor: 3.528

4.  Interobserver variability in identification of breast tumors in MRI and its implications for prognostic biomarkers and radiogenomics.

Authors:  Ashirbani Saha; Lars J Grimm; Michael Harowicz; Sujata V Ghate; Connie Kim; Ruth Walsh; Maciej A Mazurowski
Journal:  Med Phys       Date:  2016-08       Impact factor: 4.071

5.  Quantitative classification of breast tumors in digitized mammograms.

Authors:  S Pohlman; K A Powell; N A Obuchowski; W A Chilcote; S Grundfest-Broniatowski
Journal:  Med Phys       Date:  1996-08       Impact factor: 4.071

6.  Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.

Authors:  Jeong S Han; Kyle H Molberg; Venetia Sarode
Journal:  Breast J       Date:  2011-03-24       Impact factor: 2.431

7.  Usefulness of magnetic resonance in patients with invasive cancer eligible for breast conservation: a comparative study.

Authors:  Alessandro Fancellu; Daniela Soro; Paolo Castiglia; Vincenzo Marras; Marcovalerio Melis; Pietrina Cottu; Alessandra Cherchi; Angela Spanu; Silvia Mulas; Claudio Pusceddu; Luca Simbula; Giovanni B Meloni
Journal:  Clin Breast Cancer       Date:  2013-10-25       Impact factor: 3.225

8.  Radiogenomics: what it is and why it is important.

Authors:  Maciej A Mazurowski
Journal:  J Am Coll Radiol       Date:  2015-08       Impact factor: 5.532

Review 9.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.

Authors:  Beth A Virnig; Todd M Tuttle; Tatyana Shamliyan; Robert L Kane
Journal:  J Natl Cancer Inst       Date:  2010-01-13       Impact factor: 13.506

10.  Ductal carcinoma in situ diagnosed at US-guided 14-gauge core-needle biopsy for breast mass: preoperative predictors of invasive breast cancer.

Authors:  Ah Young Park; Hye Mi Gweon; Eun Ju Son; Miri Yoo; Jeong-Ah Kim; Ji Hyun Youk
Journal:  Eur J Radiol       Date:  2014-01-20       Impact factor: 3.528

View more
  3 in total

Review 1.  Machine learning in breast MRI.

Authors:  Beatriu Reig; Laura Heacock; Krzysztof J Geras; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2019-07-05       Impact factor: 4.813

Review 2.  Ductal Carcinoma in Situ: State-of-the-Art Review.

Authors:  Lars J Grimm; Habib Rahbar; Monica Abdelmalak; Allison H Hall; Marc D Ryser
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

3.  Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.

Authors:  Rui Hou; Lars J Grimm; Maciej A Mazurowski; Jeffrey R Marks; Lorraine M King; Carlo C Maley; Thomas Lynch; Marja van Oirsouw; Keith Rogers; Nicholas Stone; Matthew Wallis; Jonas Teuwen; Jelle Wesseling; E Shelley Hwang; Joseph Y Lo
Journal:  Radiology       Date:  2022-01-04       Impact factor: 29.146

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.